NHL
Copanlisib Plus Rituximab Yields Large PFS Benefit in MZL
In patients with relapsed marginal zone lymphoma, the addition of copanlisib to rituximab resulted in a 50% ...
DECEMBER 28, 2021
Copanlisib-Rituximab Combo Improves Survival for Indolent NHL
Combining copanlisib with rituximab significantly extends progression-free survival in patients with indolent ...
JUNE 18, 2021
Some Chemoimmunotherapy Regimens May Reactivate HBV in B-Cell NHL
Data from two phase 3 studies of patients with B-cell non-Hodgkin lymphoma (NHL) with resolved hepatitis B virus ...
FEBRUARY 11, 2019
FDA Approves Truxima, First Biosimilar to Rituxan
The FDA approved rituximab-abbs (Truxima, Celltrion/Teva), the first biosimilar to rituximab (Rituxan, ...
DECEMBER 1, 2018
Dr. Craig Portell Discusses Clinical Updates Related to NHL
At the 2017 Community Oncology Alliance meeting, Craig Portell, MD, at the Emily Couric Cancer Center at University ...
MAY 31, 2017
CAR T-Cell Study in NHL Patients Shows Activity and Feasibility
San Diego—Once again, a study has found that chimeric antigen receptor (CAR) T cells have impressive activity ...
APRIL 5, 2017
Obinutuzumab Increased OS In Refractory Indolent NHL Pts
San Diego—Obinutuzumab plus bendamustine followed by obinutuzumab maintenance provides an overall survival ...
FEBRUARY 9, 2017
Experimental T-Cell Therapy Shows Promise for Advanced NHL
Fifty percent of patients with advanced non-Hodgkin lymphoma who received lymphodepletion with cyclophosphamide and ...
SEPTEMBER 27, 2016
